The Journal of Thoracic and Cardiovascular Surgery
Volume 140, Issue 1 , Pages 169-173 , July 2010

The impact of bridge-to-transplant ventricular assist device support on survival after cardiac transplantation

Presented at the 32nd Annual Meeting of the Western Thoracic Surgical Association, June 24–27, 2009, Banff, Alberta, Canada.

  • David A. Bull, MD

      Affiliations

    • Division of Cardiothoracic Surgery, Department of Surgery, University of Utah Health Sciences Center, Salt Lake City, Utah
    • Corresponding Author InformationAddress for reprints: David A. Bull, MD, Professor of Surgery, Division of Cardiothoracic Surgery, University of Utah Health Sciences Center, Room 3C127, 30 North 1900 East, Salt Lake City, UT 84132.
    • ,
  • Bruce B. Reid, MD

      Affiliations

    • Division of Cardiothoracic Surgery, Department of Surgery, Intermountain Medical Center, Murray, Utah
    • ,
  • Craig H. Selzman, MD

      Affiliations

    • Division of Cardiothoracic Surgery, Department of Surgery, University of Utah Health Sciences Center, Salt Lake City, Utah
    • ,
  • Rebecca Mesley, BS

      Affiliations

    • Division of Cardiothoracic Surgery, Department of Surgery, University of Utah Health Sciences Center, Salt Lake City, Utah
    • ,
  • Stavros Drakos, MD

      Affiliations

    • Department of Cardiology, Intermountain Medical Center, Murray, Utah
    • ,
  • Steven Clayson, MD

      Affiliations

    • Division of Cardiothoracic Surgery, Department of Surgery, Intermountain Medical Center, Murray, Utah
    • ,
  • Greg Stoddard, PhD

      Affiliations

    • University of Utah Study Design and Biostatistics Center, Salt Lake City, Utah
    • ,
  • Edward Gilbert, MD

      Affiliations

    • Department of Cardiology, University of Utah Health Sciences Center, Salt Lake City, Utah
    • ,
  • Josef Stehlik, MD

      Affiliations

    • Department of Cardiology, University of Utah Health Sciences Center, Salt Lake City, Utah
    • ,
  • Feras Bader, MD

      Affiliations

    • Department of Cardiology, University of Utah Health Sciences Center, Salt Lake City, Utah
    • ,
  • Abdallah Kfoury, MD

      Affiliations

    • Department of Cardiology, Intermountain Medical Center, Murray, Utah
    • ,
  • Deborah Budge, MD

      Affiliations

    • Department of Cardiology, Intermountain Medical Center, Murray, Utah
    • ,
  • David D. Eckels, PhD

      Affiliations

    • Department of Pathology, University of Utah Health Sciences Center, Salt Lake City, Utah
    • ,
  • Anne Fuller, BS

      Affiliations

    • Department of Pathology, University of Utah Health Sciences Center, Salt Lake City, Utah
    • ,
  • Dale Renlund, MD

      Affiliations

    • Department of Cardiology, Intermountain Medical Center, Murray, Utah
    • ,
  • Amit N. Patel, MD

      Affiliations

    • Division of Cardiothoracic Surgery, Department of Surgery, University of Utah Health Sciences Center, Salt Lake City, Utah

Received 18 June 2009 ,Revised 5 March 2010 ,Accepted 21 March 2010.

References 

  1. Aaronson KD, Eppinger MJ, Dyke DB, Wright S, Pagani FD. Left ventricular assist device therapy improves utilization of donor hearts. J Am Coll Cardiol. 2002;39:1247–1254
  2. Arabia FA, Smith RG, Rose DS, Arzouman DA, Sethi GK, Copeland JG. Success rates of long-term circulatory assist devices used currently for bridge to heart transplantation. ASAIO J. 1996;42:M542–M546
  3. Jaski BE, Kim JC, Naftel DC, Jarcho J, Costanzo MR, Eisen HJ, et al. Cardiac Transplant Research Database Research Group. Cardiac transplant outcome of patients supported on left ventricular assist device vs intravenous inotropic therapy. J Heart Lung Transplant. 2001;20:449–456
  4. Pagani FD, Dyke DB, Wright S, Cody R, Aaronson KD. Development of anti-major histocompatibility complex class I or II antibodies following left ventricular assist device implantation: effects on subsequent allograft rejection and survival. J Heart Lung Transplant. 2001;20:646–653
  5. Sun BC, Catanese KA, Spanier TB, Flannery MR, Gardocki MT, Marcus LS, et al. 100 long-term implantable left ventricular assist devices: the Columbia Presbyterian interim experience. Ann Thorac Surg. 1999;68:688–694
  6. Patiolla V, Patten RD, Denofrio D, Konstam MA, Krishnamani R. The effect of ventricular assist devices on post-transplant mortality: an analysis of the United Network for Organ Sharing thoracic registry. J Am Coll Cardiol. 2009;53:264–271
  7. McKenna DH, Eastlund T, Segall M, Noreen HJ, Park S. HLA alloimmunization in patients requiring ventricular assist device support. J Heart Lung Transplant. 2002;21:1218–1224
  8. Massad MG, Cook DJ, Schmitt SK, Smedira NG, McCarthy JF, Vargo RL, et al. Factors influencing HLA sensitization in implantable LVAD recipients. Ann Thorac Surg. 1997;64:1120–1125
  9. Moazami N, Itescu S, Williams MR, Argenziano M, Weinberg A, Oz MC. Platelet transfusions are associated with the development of anti-major histocompatibility complex class I antibodies in patients with left ventricular assist support. J Heart Lung Transplant. 1998;17:876–880
  10. Stringham JC, Bull DA, Fuller TC, Kfoury AG, Taylor DO, Renlund DG, et al. Avoidance of cellular blood product transfusions in LVAD recipients does not prevent HLA allosensitization. J Heart Lung Transplant. 1999;18:160–165
  11. Drakos SG, Stringham JC, Long JW, Gilbert EM, Fuller TC, Campbell BK, et al. Prevalence and risks of allosensitization in HeartMate left ventricular assist device recipients: the impact of leukofiltered cellular blood product transfusions. J Thorac Cardiovasc Surg. 2007;133:1612–1619
  12. Joyce DL, Southard RE, Torre-Amione G, Noon GP, Land GA, Loebe M. Impact of left ventricular assist device (LVAD)-mediated humoral sensitization on post-transplant outcomes. J Heart Lung Transplant. 2005;24:2054–2059
  13. Shuhaiber J, Hur K, Gibbons R. Does the type of ventricular assisted device influence survival, infection, and rejection rates following heart transplantation?. J Card Surg. 2009;24:250–255
  14. Klotz S, Stypmann J, Welp H, Schmid C, Drees G, Rukosujew A, et al. Does continuous flow left ventricular assist device technology have a positive impact on outcome pretransplant and posttransplant?. Ann Thorac Surg. 2006;82:1774–1778
  15. Itescu S, John R. Interactions between the recipient immune system and the left ventricular assist device surface: immunological and clinical implications. Ann Thorac Surg. 2003;75(6 suppl):S58–S65
  16. Schuster M, Kocher AA, John R, Kukuy E, Edwards NM, Oz MC, et al. Allosensitization following left ventricular assist device (LVAD) implantation is dependent on CD4-CD40 ligand interactions. J Heart Lung Transplant. 2001;20:211–212
  17. Schuster M, Kocher A, John R, Hoffman M, Ankersmit J, Lietz K, et al. B-cell activation and allosensitization after left ventricular assist device implantation is due to T-cell activation and CD40 ligand expression. Hum Immunol. 2002;63:211–220
  18. Grinda JM, Bricourt MO, Amrein C, Salvi S, Guillemain R, Francois A, et al. Human leukocyte antigen sensitization in ventricular assist device recipients: a lesser risk with the DeBakey axial pump. Ann Thorac Surg. 2005;80:945–949
  19. George I, Colley P, Russo MJ, Martens TP, Burke E, Mehmet C, et al. Association of device surface and biomaterials with immunologic sensitization after mechanical support. J Thorac Cardiovasc Surg. 2008;135:1372–1379

 Disclosures: None.

PII: S0022-5223(10)00321-1

doi: 10.1016/j.jtcvs.2010.03.026

The Journal of Thoracic and Cardiovascular Surgery
Volume 140, Issue 1 , Pages 169-173 , July 2010

Article Tools

* Image Usage & Resolution